EU support for Health Research from FP6 to FP7
|
|
- Irma Preston
- 6 years ago
- Views:
Transcription
1 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006
2 EU research programmes managed by the European Commission From the Sixth Framework Programme (FP6) to the Seventh Framework Programme (FP7) The details of the FP7 priorities and modalities are still in negotiation and subject to change. In particular the European Commission s proposal for the Joint Technology Initiative for Innovative Medicines will be subjected to the express approval of the European Council.
3 Role of the EC in research European Commission programmes bring down barriers between countries: multinational consortia coordination of national funding programmes researchers from almost any country in the world can participate in EU research projects. between different types of organizations: universities, research centres, SMEs, large companies, NGOs, etc. between disciplines: increased focus on translational research and encourages mobility: Marie Curie fellowships available for researchers and for host institutes, including ingoing & outgoing grants.
4 EC Research Framework Programme 6 ( ) Health research priority ~ 2.4 billion for research 540 projects: 114 Integrated Projects (IPs), 40 Networks of Excellence (NoEs) & 284 Specific Targeted Research Projects (STREPs) Topics are set by the EC following consultation Projects are evaluated by independent experts Average success rate: 24% Consortia receive EC funding for R&D tasks (shared cost) and for project management
5 the Seventh Framework Programme ( )
6 FP7: main elements Annual budget to be increased gradually (+75% by 2013) European Research Council (Ideas) Collaborative research (Cooperation) continuity in themes & instruments, longer duration. funding levels (50%) to be raised in specific cases (+25%) Joint Technology Initiatives Infrastructures, SMEs, regions & potential (Research Capacities) Human potential and science careers (People) Reminder: The European Commission currently manages about 5% of total public spending in R&D in the European Union The European Union currently invests about 1.9% of GDP in research
7 FP7: Cooperation Collaborative research 9 Thematic Priorities Health Food, agriculture and biotechnology Information and communication technologies Nanosciences, nanotechnologies, materials and new production technologies Energy Environment (including climate change) Transport (including aeronautics) Socio-economic sciences and the humanities Security and space + Euratom: Fusion energy research, nuclear fission and radiation protection
8 Collaborative research in Framework programme 7 for Health Main policy drivers: Improving the health of European citizens Increasing the competitiveness of European health-related industries and businesses Addressing global health issues, including emerging epidemics
9 FP7 Collaborative research in Framework programme 7 Health Budget: 5984 million over 7 years ( ) Activities in 3 main areas Biotechnology, generic tools and technologies for human health Translating research for human health Optimising the delivery of healthcare
10 Collaborative research in Health FP7 1: Biotechnology, generic tools and technologies High-throughput research (enhancing data generation, standardisation, acquisition & analysis). Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches). Innovative therapeutic approaches and interventions (with potential application in many diseases and disorders). Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, including simulation, pharmacogenomics, targeting approaches and alternatives to animal testing)
11 Collaborative research in Health FP7 2: Translating research for human health Integrating biological data and processes: (large-scale data gathering, systems biology) Research on the brain and related diseases, human development and ageing Translational research in infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics) Translational research in other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)
12 Collaborative research in Health FP7 3: Optimising the delivery of health care Enhanced health promotion and disease prevention (providing evidence of best public health measures life styles, interventions, special focus on mental health, etc.) Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.) Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems, etc.)
13 Collaborative research in Health FP7 Two other issues will be addressed across activities: Child health The health of the ageing population More information: See Specific programme:
14 Collaborative research in Health FP7 Next steps: Approval by Council and European Parliament Preparation of work programmes for years 1 & 2. Currently consulting Advisory Group & Member States (PC) Launch of first calls for proposals: Dec. 06 (tbc)
15 Collaborative research in Health FP7 Funding instruments proposed: Collaborative projects to develop new knowledge, new technology, products, demonstration activities Small or medium-sized focused research actions Large-scale integrating projects Projects targeted at special groups Networks of Excellence Coordination and support actions Support for frontier research (individual teams) => ERC Support for training and career development of researchers Research for the benefit of specific groups (in particular SMEs)
16 Health research in FP7 FP7 SUMMARY Continuity in collaborative research to: develop new tools and technologies promote translational research enhanced efforts to optimise delivery of health care [ using usual FP funding and coordination mechanisms ] & A novel approach to improve drug development: The Innovative Medicines Initiative [ using the proposed Joint Technology Initiative in FP7 ]
17 European Platform Innovative Medicines Initiative
18 Innovative Medicines Initiative Starting point: drug development: increasing cost, duration and risk competitiveness of pharma industry affected EU concerned by loss of leadership in pharma R&D Response: the Innovative Medicines Initiative collaborative effort between EC and pharma industry (EFPIA) tackle specific issues where research is the key Public Private Partnership for implementation
19 15 Medicine 10 5 years Idea Creating new medicines is a high risk journey
20 EU Challenges Biopharmaceutical R&D European, Industry and Scientific challenges Escalating, unsustainable, drug development costs High failure rates - attrition Pharmaceutical R&D moving out of Europe Public spending on health R&D lower & stagnant compared to the US Private investments in sector (VCs, etc.) much lower than the US, and increasing risk adversity among investors Scientific breakthroughs has not given the expected results Fragmentation of research efforts basic, clinical and industry
21 EU challenges Biopharmaceutical R&D Identifying research needs EC challenged industry to identify the bottlenecks to pharmaceutical innovation and where R&D is the key. Industry via EFPIA s Research Directors Group responded by identifying 4 areas for R&D in agreement with key stakeholders (patients, regulators, clinical and academic researchers, etc.): Predictive safety Predictive efficacy Knowledge management Education and training and the Innovative Medicines Initiaitve (IMI) was created
22 Innovative Medicines Initiative A collaborative effort IMI shall foster the development a new toolbox for better prediction of safety and efficacy (toxicology tests, biomarkers, clinical trials protocols, etc.) for drug developers to reduce the risk of failure during clinical trials. IMI shall provide the infrastructure for validation of the new tools in view of rapid uptake into regulatory and industry practice. IMI shall set up knowledge platform pooling data from toxicology testing and biomarker validation - will be available to all researchers (industry and academic). IMI shall not develop new medicines or new vaccines it aims at reducing the attrition rate during development of new medicines!
23 Competitive Environment in the World It will be done Innovative Medicines Initiative (EFPIA-European Commission) FDA Critical Path Initiative (NIH) Safe and Innovative Medicines (PhRMA) Biomarker Initiative (PhRMA) Critical Path Institute (University of Arizona) Center for Biomedical Innovation (MIT) Toxicogenomics Project (JPMA) Proteome Factory Consortium (JPMA) Large-scale Clinical Trial Network
24 Innovative Medicines Initiative Implementation Public Private Partnership for implementation (I) A new structure is proposed to be set up by the EC and EFPIA to implement the Innovative Medicines Initiative (IMI) in view of optimizing the use of public and private resources. The Innovative IMI is proposed to be set up as a Joint Technology Initiative (JTI) under 7th EU Framework Programme for Research (FP7). IMI s governance structure should reflect - science driven approach - the collaborative spirit between stakeholders - rapid take up of results into practice - convergence and synergies with national and international efforts
25 Innovative Medicines Initiative Implementation Public Private Partnership for implementation (II) EC and EFPIA will contribute with resources for the structure (cash) and for implementing the SRA i.e. R&D and validation activities. EC will contribute with funds for academics, SMEs, etc. and the EFPIA members with resources in kind). The research will be done by: industry, SMEs, academia, clinics, patient organizations, etc. following open calls. Rules for IPR must be fair and clear to all participants from the onset. Pending favorable decision by the European Council of Ministers, IMI should become operational by 2007
26 Innovative Medicines Initiative Added value of European level intervention Closing the gap in the innovation system The JTI will fill a gap in the European Innovation system by providing mechanisms and networks for rapid valorisation and translation of research results into methods and technologies for industry and regulatory practice. The research results to be taken up can stem from research done at national/ec/international level and from academia as well as industry. IMI is changing the focus of industry collaboration from competitive research collaborations (to develop products) to pre-competitive collaborative research on scientific challenges.
27 Innovative Medicines Initiative Added value of European level intervention Stakeholders are looking for leadership and structure The JTI will provide neutral ground for the necessary collaboration between all stakeholders thereby removing the suspicions of biased collaborations that undermines collaborations today. Aiming at structuring the strongly fragmented European research base (both national and sector fragmentation will be addressed)? ERA The necessary R&D cannot be done by any of the stakeholders group alone collaboration is necessary
28 Innovative Medicines Initiative Added value of European level intervention Industry commitment and collaboration The role of the EC has been, and will be, instrumental for the increased collaboration between companies. The EC and Industry will facilitate the participation of all stakeholder groups in the research following open calls and peer review. Research can be done by anybody as long as it is carried out in Europe. Similar activities has started in the US and Japan. Without a strong European initiative industry will increasingly move its research elsewhere
29 Innovative Medicines Initiative Indicators of success Improved cooperation between academia, industry, regulators, clinicians, SMEs, patients and policy makers More rapid valorisation of scientific breakthroughs Reduced Risk of Failure in clinical trials Stimulation Biotech-SMEs and investment in sector More resources liberated for more R&D Faster drug development time Move of attrition from late to early development phases Fewer post-marketing withdrawals Fewer patients in pivotal trials Enhance the medicine pipeline Better utilisation of more efficacious medicines
30 Innovative Medicines Initiative Next steps Next steps: Finalise SRA following open consultation Develop governance structure legal entity, governance rules & financial engineering, IPR rules Obtain approval as part of Framework programme 7 Council decision on its creation Foreseen to become operational by 2007
31 Innovative Medicines Initiative The research will be done by academia, clinics, industry, SMEs, patient organizations, etc, following open calls and peer evaluation. IMI will develop a new toolbox for better prediction of safety and efficacy (toxicology tests, biomarkers, clinical trials protocols, etc.) for drug developers to reduce the risk of failure during clinical trials. IMI shall provide the infrastructure for validation of the new tools in view of rapid uptake into regulatory and industry practice. IMI will set up knowledge platform pooling data from toxicology testing and biomarker validation - will be available to all researchers. IMI shall not develop new medicines or new vaccines it aims at reducing the attrition rate during development of new medicines.
32 More Information EC funded health research: Framework Programme 6 The Framework Programme 7 Innovative Medicines Initiative
Rare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationEuropean Framework for Exploring Nanotechnology
European Framework for Exploring Nanotechnology - Seventh Framework Program (FP7) Mary Kavanagh Science, Technology and Education Counselor European Commission Delegation to the USA JIFSAN, Greenbelt,
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationFunding programmes on EU level. Dr. Stephan Micha
Funding programmes on EU level - especially - FP7 - Health and FP7 - Food, Agriculture and Fisheries, and Biotechnology Dr. Stephan Micha National Contact Point Life Sciences, Germany Hanover Germany 10
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationTowards FP7 - Food, Agriculture and Biotechnology
Young Train Seminar 2 Girona, Spain Towards FP7 - Food, Agriculture and Biotechnology Cled Thomas and Jean-François Maljean FP7 2007-2013 Cooperation Collaborative research Ideas Frontier Research People
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationJOINT TECHNOLOGY INITIATIVES
JOINT TECHNOLOGY INITIATIVES in the Seventh Framework Programme Etienne Magnien Prague, 30 October, 2008 JOINT TECHNOLOGY INITIATIVES General principles 1. General principles 2. Specificities 3. Launch
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationEUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008
Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is
More informationFP Work Programmes International Dimension. Opportunities for China
FP7 2013 Work Programmes International Dimension Opportunities for China FP7 Work Programmes 2013 All relevant information available on the FP7 participants portal : http://ec.europa.eu/research/participants/portal
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More informationEFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY
EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the
More information23-26 OCTOBER 2017 INNOVATION IN ACTION EUROPEAN PARLIAMENT STRASBOURG. Meet the EU s research and innovation public-private partnerships
23-26 OCTOBER 2017 INNOVATION IN ACTION EUROPEAN PARLIAMENT STRASBOURG Meet the EU s research and innovation public-private partnerships Meet the EU s research public-private partnerships Bio-based Industries
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationMARIE CURIE ACTIONS. European Industrial Doctorates
MARIE CURIE ACTIONS European Industrial Doctorates Vanessa Debiais-Sainton Policy Officer DG Education, Culture, Multilingualism and Youth Unit C3, Marie Curie Actions AGENDA Objectives of Marie Curie
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationJOINT TECHNOLOGY INITIATIVES
JOINT TECHNOLOGY INITIATIVES Public-Private Partnerships in EU Research Foreword by Commissioners Janez Potočnick and Viviane Reding Joint Technology Initiatives are a smart new way of working together
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationWebinar IMI2 - Call 9 Data quality in preclinical research and development. Thomas Steckler IMI webinar
Webinar IMI2 - Call 9 Data quality in preclinical research and development Thomas Steckler 11.04.2016 IMI webinar Need for public-private collaboration Low quality data hamper innovation and progress in
More informationEuropean Molecular Biology Laboratory s position paper on the interim evaluation of Horizon 2020
European Molecular Biology Laboratory s position paper on the interim evaluation of Horizon 2020 I. Introduction role of EMBL in life science research in Europe The European Molecular Biology Laboratory
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationEuropean Technology Platform for Global Animal Health. Action Plan
European Technology Platform for Global Animal Health Action Plan European Technology T Platform for Global Animal Health Action Plan 2 Table of contents Executive Summary 7 Chapter 1: The Action Plan
More informationCOUNCIL DECISION. of 19 December 2006
L 400/270 EN Official Journal of the European Union 30.12.2006 COUNCIL DECISION of 19 December 2006 concerning the specific programme "People" implementing the Seventh Framework Programme of the European
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationOverview of the EC EHS research plans and perspective. FP7 and future research needs Most recent calls for proposals and those anticipated
Overview of the EC EHS research plans and perspective FP7 and future research needs Most recent calls for proposals and those anticipated European Commission Directorate-General for Research and Innovation
More informationFuture Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015
Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder
More informationDiagnostics gathering intelligence to fight antimicrobial resistance
Diagnostics gathering intelligence to fight antimicrobial resistance Arjon van Hengel European Commission DG Research and Innovation, Health Directorate Unit "Fighting Infectious Diseases and Advancing
More informationResearch and Innovation in Drug Discovery and Diagnostics
INTERNATIONAL CONFERENCE Intellectual Property and Health Innovation Challenges for the future April 28, 2014, Athens, Greece Research and Innovation in Drug Discovery and Diagnostics Alexander Pintzas,
More information2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationRail R&D in Europe New opportunities:
Rail R&D in Europe New opportunities: Horizon 2020 the EU Framework for Research & Innovation (2014-2020) 2020) Madrid, 31st of May 2012 PTFE General Assembly Johan Blondelle Research Programme Officer
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationWork programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board
18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationEuropean Research Area A MAASTRICHT FOR RESEARCH
September 2013 European Research Area A MAASTRICHT FOR RESEARCH Amalia Sartori, MEP - Chairwoman ITRE Committee Luigi Berlinguer, MEP - Former Italian Minister for Research Research and innovation are
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationNCI Research Networks Model for Collaboration with Bioelectronics Round Table
NCI Research Networks Model for Collaboration with Bioelectronics Round Table Larry Clarke, Cancer Imaging Program DCDT, NCI Detail: NIBIB Guest Scientist: NIST 1 Bioelectronics Round Table Research Triangle
More informationORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet
ORPHANET s Services for Researchers Valérie THIBAUDEAU Database Manager Orphanet Services for Researchers Needs Access classifications, genes Identify experts Collaborate Quickly recruit volunteers Establish
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationIntroduction to Horizon 2020
Introduction to Horizon 2020 20.05.2015 Michaela Pöter Management Jülich Content 1. Horizon 2020: Structure and Key Objectives 2. Priority I: Excellent Science 3. Priority II: Industrial Leadership 4.
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationDecoding Phase II Clinical Trial Terminations
Decoding Phase II Clinical Trial Terminations Why Phase II trials are terminated and what can be done to improve Phase II success rates - the most critical inflection point for clinical development Subha
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationFive years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
More informationImpact assessment of health research projects supported by DG Research and Innovation
Impact assessment of health research projects supported by DG Research and Innovation 2002-2010 Followed by: Expert group report recommendations on the future of health research in Europe 1 Foreword I
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationCOMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical
More informationRemco de Vrueh. Driving partnerships from idea to success
Remco de Vrueh Driving partnerships from idea to success Rare Disease Symposium: the rare disease patient in 2030 Outline 2 Current status Orphan drug development Public-Private Partnerships (PPPs) Lygature
More informationEFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ)
EFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ) Disclaimer I am an employee of Chiesi Farmaceutici s.p.a (Head of Clinical Safety
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationOpinions in view of the discussion of the next EU Framework Programme for Research and Innovation. Introduction and summary of comments.
Memorandum 2 November 2017 U2017/03983 Ministry of Education and Research Ministry of Enterprise and Innovation Opinions in view of the discussion of the next EU Framework Programme for Research and Innovation
More informationEthics and Clinical trials EU approach
Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President
More informationFP7 topics linked to the Transport theme in 2011
FP7 topics linked to the Transport theme in 2011 Transport theme Aeronautics and air transport (AAT) AAT.2012.1.1-1. Area Green aircraft - Flight physics or AAT.2012.1.1-2. Area Green aircraft - Aerostructures
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationA French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
More informationHealthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016
Healthy Ageing From Basic Science to Clinical Applications and New Business Jan Sikkema Center for Development and Innovation June 16, 2016 Groningen Broad Research University 11 faculties > 30.000 students
More informationVIVEK VIKRAM SINGH, SUBJECT MATTER EXPERT, RESEARCH & ANALYTICS CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG DEVELOPMENT?
VIVEK VIKRAM SINGH, SUBJECT MATTER EXPERT, RESEARCH & ANALYTICS CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG DEVELOPMENT? wns wns CAN COMPETITIVE INTELLIGENCE STRATEGIES HELP IN ORPHAN DRUG
More information«People» Marie Curie Actions
FP7 Specific Programme «People» Marie Curie Actions Georges Bingen Head of Marie Curie Fellowship unit Directorate General Research 1 Policy context: Human resources in R&D Financial instrument: Marie
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationFDA Guidance, Clinical Pharmacology, and Regulatory Science
Principles of Clinical Pharmacology NIH, April 25, 2013 FDA Guidance, Clinical Pharmacology, and Regulatory Science Carl Peck, MD UCSF Center for Drug Development Science Washington DC and San Francisco
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationJoint Technology Initiatives: Origins and Approach
Joint Technology Initiatives: Origins and Approach Presentation to Italian Association of Electrical and Electronic Industries Information Day Roma, 17 October 2007 Seán O Reagain Good morning, ladies
More informationSpecific Programme People. Marie Curie Actions. Agata Stasiak. Institutional Fellowships Directorate General Research European Commission
Specific Programme People Marie Curie Actions from the 6 th to the 7 th Framework Programme Agata Stasiak Institutional Fellowships Directorate General Research European Commission Agata.Stasiak@ec.europa.eu
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationThe European Medicines Agency: a model of patient/consumer interaction
The European Medicines Agency: a model of patient/consumer interaction V International Conference on patient safety Juan García Burgos Head of Public Information and Stakeholder Networking - Medical Information
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationCHECK AGAINST DELIVERY! Denis Roger (EDA Director ESI) : Intervention SEDE 25 January 2017 Preparatory Action in the field of Defence Research
CHECK AGAINST DELIVERY! Denis Roger (EDA Director ESI) : Intervention SEDE 25 January 2017 Preparatory Action in the field of Defence Research [Introduction] I would like to thank you for your invitation
More informationthe EU framework programme for research and innovation
High Performance Computing First Horizon 2020 Calls (2014-2015) Dr Panagiotis Tsarchopoulos Future and Emerging Technologies DG CONNECT European Commission the EU framework programme for research and innovation
More informationMedical Affairs Not a Sunshine Day Analyzing the Impact of the Sunshine Act on Medical Affairs: Challenges for 2014 and Beyond
Medical Affairs Not a Sunshine Day Analyzing the Impact of the Sunshine Act on Medical Affairs: Challenges for 2014 and Beyond Jodi Smith, PhD and Peg Crowley Nowick, PhD, MBA Medical Affairs Not a Sunshine
More informationict Multi-Year Grants Funding Opportunity
ict Multi-Year Grants Funding Opportunity Overview Background Strategy for Patient- Oriented Research (SPOR) Innovative Clinical Trials initiative (ict) SPOR and JDRF Partnership on Innovative Clinical
More informationOrphan designation in the EU
Orphan designation in the EU EURORDIS summer school Barcelona, June 2013 Presented by: Jordi Llinares Head of Orphan Medicines An agency of the European Union Outline Overview orphan designation Procedure
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More information28 February Miroslav Lajčák. All Permanent Representatives and Permanent Observers to the United Nations New York
THE PRESIDENT OF THE GENERAL ASSEMBLY 28 February 2018 Excellency, I am pleased to inform You that consensus has been reached on the draft resolution on the scope, modalities, format and organization of
More informationCOMMUNICATION FROM THE COMMISSION. on the European Citizens' Initiative "Stop Vivisection"
EUROPEAN COMMISSION Brussels, 3.6.2015 C(2015) 3773 final COMMUNICATION FROM THE COMMISSION on the European Citizens' Initiative "Stop Vivisection" EN EN 1. INTRODUCTION "Stop Vivisection" is the third
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More information